BOYNTON BEACH, Fla.--(BUSINESS WIRE)--Inside CSCI's Multi-Generational Workforce and the Family-Driven Culture Behind Florida's Fast-Growing Shell Construction Leader. ...

Core Viewpoint - COSCIENS Biopharma Inc. has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited for the commercialization of Macrilen in specific Asian markets, aiming to address the unmet need for growth hormone deficiency diagnostics [1][2][3]. Company Overview - COSCIENS Biopharma Inc. focuses on pharmaceutical therapies, diagnostic products, and natural ingredient solutions, with a diverse portfolio that includes the development of natural, plant-based active ingredients [5]. - The company's lead product, Macrilen (macimorelin), is the first and only FDA and EMA approved oral test for diagnosing Adult Growth Hormone Deficiency (AGHD) [6]. Distribution Agreement Details - The agreement with Wuzhou covers the registration, importation, and commercialization of Macrilen in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan [2]. - The partnership is structured for an initial ten-year term, with Wuzhou committing to a minimum initial order of approximately €800,000 [2]. Strategic Importance - The collaboration is expected to leverage the "Hong Kong and Macao Medicine and Equipment Connect" policy, facilitating expedited market access in the Guangdong-Hong Kong-Macao Greater Bay Area [2]. - The agreement is seen as a key step in COSCIENS' strategy to unlock the global potential of Macrilen and establish sustainable revenue streams [3]. Market Potential - The partnership aims to meet the significant demand for a convenient, oral diagnostic option for patients suspected of AGHD in the dynamic Asian markets [3]. - Wuzhou's expertise in regulatory processes and hospital networks is expected to enhance the approval pathways for Macrilen in the targeted regions [4].

Core Insights - CSCI, a leading structural shell contractor in Florida, is experiencing market growth under the leadership of President Daniel Goldburg [1] Company Overview - CSCI is recognized as one of Florida's pre-eminent structural shell contractors [1] - The company is entering a new era of operations and growth [1]

Core Points - COSCIENS Biopharma Inc. has appointed Peter H. Puccetti as Interim Chief Executive Officer, succeeding Anna Biehn [1][2] - The leadership transition is part of the company's efforts to reduce costs and streamline its organizational structure while aligning resources with strategic priorities [2] - Puccetti aims to strengthen operational performance and drive shareholder value in his new role [2] Company Overview - COSCIENS is a life science company focused on natural ingredients and pharmaceutical solutions, with a diverse portfolio [3] - The company develops natural, plant-based active ingredients and commercializes pharmaceutical and diagnostic products [3] - COSCIENS' lead pharmaceutical product, Macimorelin, is the first FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [3] Stock Information - COSCIENS' common shares are listed on the Toronto Stock Exchange under the symbol "CSCI" and have a trading symbol "CSCIF" for the OTC market in the United States [4]

Core Insights - COSCIENS Biopharma Inc. has voluntarily delisted from Nasdaq while retaining its listing on the TSX, marking a strategic shift to reduce public reporting obligations in the U.S. [4][5] - The company has successfully implemented a zero-based budgeting initiative, resulting in a 59% reduction in operating expenses compared to Q3 2024, leading to significantly lower cash outflows [3][15] - The gross margins improved by 700 basis points in Q3 2025 due to cost-cutting measures and operational improvements [2][3] Financial Performance - For Q3 2025, COSCIENS reported a consolidated net loss of $1.8 million, a decrease from a net loss of $5.8 million in Q3 2024, reflecting a $4.0 million improvement [15][18] - Total revenue for Q3 2025 was $1.5 million, down from $1.9 million in the same period in 2024, primarily due to decreased sales in key product lines [16][19] - Operating expenses for Q3 2025 were $2.9 million, significantly lower than $7.3 million in Q3 2024, driven by reductions in research and development costs and other expenses [17][20] Strategic Developments - The company has suspended its Juvente cosmeceuticals line due to limited success in e-commerce channels, focusing instead on core business areas [8] - COSCIENS is evaluating its pharmaceutical products, including Macrilen, which did not meet primary endpoints in a recent trial but still provides insights for future development [12] - The company is exploring new market opportunities for its active ingredients and has completed construction of its PGX technology units in Edmonton and Austria [10][11] Corporate Actions - Following the Nasdaq delisting, COSCIENS has applied for quotation on the OTCQB Venture Market, although approval is not guaranteed [4] - The company plans to file a Form 15-F with the SEC to terminate its U.S. reporting obligations, which would take effect 90 days after filing [4][5] - Management is focused on enhancing operational efficiency and reducing costs to maintain competitiveness in the current economic environment [5]

Core Viewpoint - COSCIENS Biopharma Inc. has approved a plan to voluntarily delist from Nasdaq while maintaining its listing on the Toronto Stock Exchange (TSX) to focus resources on core business needs and enhance operational efficiency [1][8]. Financial Highlights - For Q2 2025, total revenue was $2.7 million, a 17% increase compared to $2.3 million in Q2 2024 [17]. - Gross profit for Q2 2025 increased by 19% compared to the same period in 2024 [7]. - Operating expenses decreased by 28% compared to Q2 2024, totaling $3.3 million [18]. Strategic and Operational Updates - The company underwent a leadership change with a new CEO and a reconstituted Board of Directors, focusing on operational discipline and cost control [4][3]. - A zero-based budgeting initiative was launched, resulting in a 27% reduction in headcount to align costs with strategic priorities [6]. - The company is focusing on optimizing its revenue-generating base business and exploring new business development opportunities [5]. Nasdaq Delisting - The decision to delist from Nasdaq was driven by increasing costs associated with maintaining dual listings and a deteriorating cost-benefit ratio [8]. - The company plans to file a Form 25 with the SEC around August 25, 2025, with the delisting expected to be effective on or about September 5, 2025 [9][10]. Product and Market Development - The company is exploring new category expansion opportunities for its active ingredients, including beta glucan and avenanthramides [14]. - Despite challenges in the Macrilen product line, the company is assessing future development options and has ongoing clinical studies for its inflammation-related program [14]. Cash Position - As of June 30, 2025, the company had $9.3 million in cash and cash equivalents [15]. Overall Performance - For the six-month period ended June 30, 2025, the company reported a consolidated net loss of $6.0 million, compared to a loss of $2.8 million for the same period in 2024 [19]. - Total revenue for the six-month period was $4.2 million, a slight decrease from $4.4 million in the prior year [20].

Core Viewpoint - COSCIENS Biopharma Inc. held its annual general and special meeting of shareholders, where key voting results were announced, including the election of directors and the appointment of auditors [1][2]. Voting Results - Peter H. Puccetti was elected as Chair with 580,289 votes for (88.92%) and 72,286 votes against (11.08%) [2] - Anthony J. Giovinazzo received 574,954 votes for (88.11%) and 77,621 votes against (11.89%) [2] - Ulrich Kosciessa garnered 580,140 votes for (88.90%) and 72,435 votes against (11.10%) [2] - Ronald W. Miller was elected with 448,646 votes for (68.75%) and 203,929 votes against (31.25%) [2] - Robert A. Seager received 580,254 votes for (88.92%) and 72,321 votes against (11.08%) [2] - David Spear had 580,106 votes for (88.89%) and 72,469 votes against (11.11%) [2] - Deloitte LLP was appointed as the Company's auditor [2] - An ordinary resolution to approve the Company's Amended and Restated Shareholder Rights Plan was also approved [2]. Company Overview - COSCIENS Biopharma Inc. is a life sciences company focused on developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products [5]. - The company utilizes proprietary extraction technology for producing active ingredients from renewable plant resources, which are used in leading skincare brands [5]. - The portfolio includes macimorelin (Macrilen; Ghryvelin), the first and only FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [5]. Listing Information - COSCIENS is listed on both the NASDAQ Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [6].

Corporate Governance - Peter H. Puccetti was elected as Chair with 580,289 votes, representing 88.92% approval[2] - Deloitte LLP was appointed as the Company's auditor with 1,043,647 votes in favor, accounting for 93.55%[13] - The Amended and Restated Shareholder Rights Plan was approved with 521,610 votes for, which is 79.93%[13] - Ronald W. Miller received the lowest approval at 68.75%, with 448,646 votes for and 203,929 votes against[2] - The voting results were filed on SEDAR+ and EDGAR for public access[4] Business Operations - The Company has a diversified portfolio including macimorelin, the first FDA and EMA approved oral test for adult growth hormone deficiency[5] - The Company is listed on both NASDAQ and TSX under the ticker symbol "CSCI"[6] - The Company has relied on an exemption from certain Canadian requirements regarding its long-term incentive plan[3] Risk Management - Forward-looking statements indicate potential risks related to product development and market performance[9] - The Company emphasizes the importance of securing strategic partners for late-stage development and marketing[9]

Core Viewpoint - COSCIENS Biopharma Inc. has entered into a resolution agreement with Goodwood to reconstitute its board of directors, aiming to enhance shareholder value and corporate governance [2][3][5]. Board Reconstitution - The board now consists of six directors: Anthony J. Giovinazzo, Ulrich Kosciessa, Ronald W. Miller, Peter H. Puccetti, Robert A. Seager, and David Spear [3][4]. - The 2025 Annual Meeting has been postponed to June 30, 2025, to allow for the timely dissemination of management information [4]. Shareholder Support - Goodwood, which holds approximately 8.2% of COSCIENS' outstanding common shares (257,257 shares), has agreed to vote in favor of the re-election of the six directors at the upcoming meeting [4]. Governance Commitment - The Reconstituted Board is dedicated to strong corporate governance and effective oversight, with plans to actively review COSCIENS' prospects and opportunities [5]. Director Profiles - **Anthony J. Giovinazzo**: Over 45 years of executive experience, previously CEO of Cynapsus Therapeutics, instrumental in its successful IPO and acquisition [7][9]. - **Ulrich Kosciessa**: CEO of Photonamic GmbH, extensive experience in global pharmaceutical operations, and significant growth achievements [10][11]. - **Ronald W. Miller**: Former President and CEO of Hoffmann-La Roche Limited in Canada, with over 43 years in the pharmaceutical industry [12]. - **Peter H. Puccetti**: Founder and CIO of Goodwood Inc., known for leading activist campaigns to unlock shareholder value [13][14]. - **Robert A. Seager**: Specializes in shareholder disputes and corporate governance, currently a partner at Voorheis & Co. LLP [15][16]. - **David Spear**: Over 35 years in the healthcare industry, focusing on eyecare, and has co-founded multiple ventures [17].

Core Viewpoint - COSCIENS Biopharma Inc. has received director nominations from Goodwood Fund and Puccetti Funds Management Inc. for its upcoming Annual and Special Meeting of Shareholders, indicating potential changes in governance and strategic direction [1][2]. Company Overview - COSCIENS Biopharma Inc. is a life sciences company focused on developing and commercializing a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products, utilizing proprietary extraction technology from renewable plant resources [3]. - The company's product portfolio includes macimorelin (Macrilen®; Ghryvelin®), which is the first and only FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [3]. Market Position - COSCIENS is publicly traded on both the NASDAQ Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [4].